RUCONEST

Hear from a Hereditary Angioedema Expert

Learn about the comprehensive treatment of HAE with C1-INH therapy.

Ruconest is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

See Important Safety Information below.

*Indicates a required field

One test kit per registration, while supplies last, delivery prior to program not guaranteed by Pharming

Only physicians and healthcare professionals who are or may be involved in providing HAE patient care or product recommendations may attend this educational program.

Only physicians and healthcare professionals who are or may be involved in providing HAE patient care or product recommendations may attend this educational program.

Thank you for registering!

Please visit ExploreHAE.com for resources about HAE and RUCONEST.

There was a problem

Please check your information and try again

Return to form

Toggle ISI

INDICATION

Ruconest is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

IMPORTANT SAFETY INFORMATION

RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.

Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). Should symptoms occur, discontinue RUCONEST and administer appropriate treatment.

Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.

Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer dose of RUCONEST.

The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea. No more than 2 doses should be administered within a 24-hour period.

Before prescribing RUCONEST, please read the full accompanying prescribing information.

This program is sponsored by Pharming. Only healthcare professionals who are or may be involved in providing HAE patient care or product recommendations may also attend this non-CME educational program. Healthcare professionals may not bring their own guests or spouses to the program unless they meet requirements noted previously. Please note: Healthcare professionals in attendance will have their name and the value of any meal/refreshment reported as required by federal and state laws. Any healthcare professionals maintaining a license to practice medicine in Minnesota, Vermont or New Jersey must notify the Pharming representative upon sign-in.

Pharming adheres to COVID-19 guidelines and recommends all Pharming employees, speakers, and attendees test within 48 hours before the event. Pharming will provide a free COVID-19 test via the mail if requested at least 2 business days prior to the event. If you test positive or are experiencing COVID-19 symptoms, please stay home.